MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

long‑acting injectable

Search medical newsFind research, conditions and clinical updates
  • Home
  • long‑acting injectable
长效注射HIV治疗:改善非洲依从性困难成人的病毒抑制
Posted inHIV/AIDS Infectious Diseases news

Long-Acting Injectable HIV Therapy: Improving Viral Suppression in African Adults with Adherence Challenges

Posted by By MedXY 10/18/2026
A Phase 3b trial in eastern and southern Africa showed that long-acting injectable cabotegravir plus rilpivirine is noninferior to oral dolutegravir-based therapy for maintaining viral suppression in HIV patients facing adherence challenges.
Read More
Long‑acting Cabotegravir–Rilpivirine Achieves Durable Viral Suppression at 96 Weeks in African CARES Trial: A Practical Leap for HIV Treatment Delivery
Posted inInfectious Diseases news

Long‑acting Cabotegravir–Rilpivirine Achieves Durable Viral Suppression at 96 Weeks in African CARES Trial: A Practical Leap for HIV Treatment Delivery

Posted by By MedXY 11/13/2025
The CARES phase 3b trial in Africa found cabotegravir + rilpivirine long‑acting injections every 8 weeks noninferior to continued oral ART for viral suppression at 96 weeks, with an acceptable safety profile and implementation considerations for African programmes.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Beyond Abstinence: Multidisciplinary Approaches Enhance Long-Term Outcomes After Liver Transplantation for Alcohol-Associated Liver Disease
  • Assessing Accuracy and Utility of Melanoma Risk Prediction Models in an Australian Cohort
  • A Minimum Standard Set for Reporting Lymphatic Surgery Outcomes: What the Society of Lymphatic Surgery Consensus Means for Practice
  • Putting People First in ICU Care: ESICM’s 2026 Consensus on Human-Centred Partnership
  • Force Multiplication in Body Contouring: Enhancing Access and Conversion through Advanced Practice Provider Clinics
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top